Science

US begins trial for a second potential COVID-19 vaccine candidate

Hemani Sheth Mumbai | Updated on April 07, 2020 Published on April 07, 2020

Representative Image   -  AFP

Inovio plans to have one million doses of the vaccine available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding

In US’ second clinical human testing for COVID-19 vaccines, a new vaccine candidate entered Phase 1 clinical human testing on Monday after the US Food and Drug Administration (FDA) accepted Inovio Pharmaceuticals’ Investigational New Drug (IND) application for INO-4800 vaccine candidate.

The company, backed by collaborators that include the Bill and Melinda Gates foundation is testing its DNA vaccine candidate designed to prevent COVID-19 infection with clinical testing in healthy volunteers beginning this week.

It will enrol up to 40 candidates in its Phase 1 study of the vaccines INO-4800 will enrol up to 40 in Philadelphia, PA (at the Perelman School of Medicine at the University of Pennsylvania) and Kansas City, MO (at the Center for Pharmaceutical Research).

Clnical Testing scope

“Each participant will receive two doses of INO-4800 four weeks apart, and the initial immune responses and safety data from the study are expected by late summer,” it said.

The company has based the virus on findings from its previous study for a DNA vaccine candidate for Middle East Respiratory Syndrome (MERS) which had shown promising results.

“Additional preclinical trials, including challenge studies, will continue in parallel with the Phase 1 clinical trial,” it further said.

The vaccine candidate works by injecting an independent genetic structure called plasmid into a patient. It helps the patient in producing an effective antibody that fights of the coronavirus infection.

The company will proceed on to Phase 2 after attaining initial safety and immunogenicity data from Phase 1 studies.

Other aspects of the project

Inovio plans to have one million doses of the vaccine available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding, it said.

Apart from the Bill and Melinda Gates Foundation, the study is supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and VGXI, Inc., a wholly-owned subsidiary of GeneOne Life Science.

This is the second clinical trial for a COVID-19 vaccine with human volunteers. The US began its first human trial for a vaccine in March at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle where the first participant received an investigational vaccine to combat the virus which has now infected over 1.2 million people across the globe.

Published on April 07, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.